Providers should weigh discontinuation decisions carefully in these populations and discuss restart plans proactively if stopping is unavoidable
The increased use of GLP-1 medications presents an exciting opportunity to support Americans managing diabetes and weight loss, as well as those seeking to lead a healthier lifestyle, said Bob Nolan, vice president of demand science at Conagra Brands
It should not be used by people who: Have a personal or family history of medullary thyroid carcinoma Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Have a known allergy or hypersensitivity to orforglipron or any of the components of the tablet Are pregnant, planning pregnancy in the near future, or breastfeeding Are already using another GLP-1 receptor agonist (combining them is not recommended) Caution is also advised in patients with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease such as gastroparesis, or significant kidney disease
Human Drug Compounding Under Section 503A of the FD&C Act
The G-site is predominantly contained in the N-terminal domain and binds GSH and primes the thiol sulfur for nucleophilic attack on an electrophilic substrate [77-79]
My REM sleep dropped by 23%
